Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

Biogen has said it hopes new “real world” data will ensure patients are not put off taking its key multiple sclerosis drug, Tecfidera because of stomach problems that can occur early in treatment.

Tecfidera (dimethyl fumarate) can cause side effects that range from mild to serious. More common side effects include flushing and abdominal pain. If side effects from Tecfidera become difficult ...